Inhibitor Working Party

Membership

Dr Charles Percy	Chair
Dr John Grainger	
Dr Dan Hart	
Prof Mike Makris	
Dr Mary Mathias	
Ben Palmer	
Dr Anne Riddell	
Dr Kate Talks	

Meetings

The inhibitor working party (IWP) has met three times online since December 2020. It continues to benefit from membership from various disciplines and across a number of related working parties. Discussions and activity have encompassed a variety of areas.

Activities

Firstly, modifying and developing forms for reporting inhibitors to the National Haemophilia Database (NHD). The report form for new factor VIII inhibitors in congenital haemophilia A has been updated to allow reporting events on emicizumab. New report forms have been drafted for inhibitors developing in congenital Von Willebrand's disease. These will hopefully be implemented in due course.

Secondly, in conjunction with the paediatric working party (PWP), interim guidance has been issued on monitoring for new factor VIII inhibitors in patients receiving prophylaxis with emicizumab. It is important for clinicians to remain vigilant and report new events promptly. At present the numbers are low and the paucity of data renders it difficult to make firm recommendations as to the most appropriate course of action when such an event occurs. Both the IWP and PWP can be approached to discuss cases where clinicians wish to do so.

Thirdly, revised guidance on immune tolerance induction has now been published and the reference is listed below. Attention will next focus on a revision the existing guideline on acquired coagulation factor inhibitors to take account of new data.

Fourthly, progress on analysing the data centres have submitted as part of the acquired haemophilia A data collection project has been slower than intended. This is due in part to the impact of the COVID-19 pandemic on the working arrangements of members of the IWP and the staff at the NHD, and partly due to the resources the NHD has needed to focus on responding to the Infected Blood Inquiry.

Publications

Haemophilia. 2021 Aug 17. doi: 10.1111/hae.14381.

Dr Charles Percy
Chair, Inhibitor Working Party
October 2021